Browsing by author "Pedersen, Malin"
Now showing items 1-8 of 8
-
ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment.
Dillon, MT; Bergerhoff, KF; Pedersen, M; Whittock, H; Crespo-Rodriguez, E; et al. (AMER ASSOC CANCER RESEARCH, 2019-06-01)PURPOSE: ATR inhibitors (ATRi) are in early phase clinical trials and have been shown to sensitize to chemotherapy and radiotherapy preclinically. Limited data have been published about the effect of these drugs on the ... -
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.
Bozhanova, G; Hassan, J; Appleton, L; Jennings, V; Foo, S; et al. (BMJ PUBLISHING GROUP, 2022-03-01)BACKGROUND: Combination herpes simplex virus (HSV) oncolytic virotherapy and BRAF inhibitors (BRAFi) represent promising immunogenic treatments for BRAF mutant melanoma, but an improved understanding of the immunobiology ... -
Characterization of proteome-size scaling by integrative omics reveals mechanisms of proliferation control in cancer.
Jones, I; Dent, L; Higo, T; Roumeliotis, T; Arias Garcia, M; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2023-01-25)Almost all living cells maintain size uniformity through successive divisions. Proteins that over and underscale with size can act as rheostats, which regulate cell cycle progression. Using a multiomic strategy, we leveraged ... -
Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status.
Hafsi, H; Dillon, MT; Barker, HE; Kyula, JN; Schick, U; et al. (FRONTIERS MEDIA SA, 2018-07-13)Head and neck squamous cell carcinoma (HNSCC) is a significant cause of cancer deaths. Cisplatin-based chemoradiotherapy is a standard of care for locally advanced disease. ATR and DNA-PK inhibition (DNA-PKi) are actively ... -
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer.
Crespo-Rodriguez, E; Bergerhoff, K; Bozhanova, G; Foo, S; Patin, EC; et al. (BMJ PUBLISHING GROUP, 2020-01-01)BACKGROUND: The aggressive clinical behavior of poorly differentiated and anaplastic thyroid cancers (PDTC and ATC) has proven challenging to treat, and survival beyond a few months from diagnosis is rare. Although 30%-60% ... -
Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.
Patin, EC; Dillon, MT; Nenclares, P; Grove, L; Soliman, H; et al. (BMJ PUBLISHING GROUP, 2022-03-01)BACKGROUND: Despite therapeutic gains from immune checkpoint inhibitors (ICI) in many tumor types, new strategies are needed to extend treatment benefits, especially in patients failing to mount effective antitumor T-cell ... -
Inflammatory microenvironment remodelling by tumour cells after radiotherapy.
McLaughlin, M; Patin, EC; Pedersen, M; Wilkins, A; Dillon, MT; et al. (NATURE PORTFOLIO, 2020-04-01)The development of immune checkpoint inhibitors (ICIs) is revolutionizing the way we think about cancer treatment. Even so, for most types of cancer, only a minority of patients currently benefit from ICI therapies. Intrinsic ... -
The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism.
McLaughlin, M; Pedersen, M; Roulstone, V; Bergerhoff, KF; Smith, HG; et al. (CELL PRESS, 2020-03-27)Reovirus type 3 Dearing (reovirus) is a tumor-selective oncolytic virus currently under evaluation in clinical trials. Here, we report that the therapeutic efficacy of reovirus in head and neck squamous cell cancer can be ...